- Axiom plans Hong Kong IPO, hoping to carve new path for US biotechsAxiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.BioSpace · 3d ago↗ source
- Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drugJupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.Fierce Biotech · 3d ago↗ source
- Agios says adios to sickle cell program over lackluster phase 2 dataA phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…